Genomic translocation of the neurotrophic tyrosine receptor kinase gene (NTRK), which leads to the constitutive activation of receptor tyrosine kinases, is rare in pan-cancer, including CCA [29]; however, both larotrectinib and entrectinib have been approved for the treatment of cancers harboring NTRK gene rearrangements. Here, NTRK1 is linked to cancer.